Overview

Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Fasting Conditions

Status:
Completed
Trial end date:
2021-03-26
Target enrollment:
Participant gender:
Summary
This Study will investigate the bioavailability in fasting subjects of 1 capsule formulation containing Duloxetine 60 mg. The Study will be performed at a single site with 36 subjects. Participants will take 1 capsule of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 14 days between each study period.
Phase:
Phase 1
Details
Lead Sponsor:
Laboratorios Andromaco S.A.
Treatments:
Duloxetine Hydrochloride